Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2095-2128.
Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35: 2950-2959.
Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study). Eur Heart J 2010; 31: 2755-2764.
Senis YA. Protein-Tyrosine phosphatases: a new frontier in platelet signal transduction. J Thromb Haemost 2013; 11: 1800-1813.
Musumeci L, Kuijpers MJ, Gilio K, et al. Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 2015; 131: 656-668.
Tautz L, Senis YA, Oury C, Rahmouni S. Perspective: tyrosine phosphatases as novel targets for antiplatelet therapy. Bioorg Med Chem 2015; 23: 2786-2797.
Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-179.
Ungerer M, Munch G. Novel antiplatelet drugs in clinical development. Thromb Haemost 2013; 110: 868-875.
Boeynaems JM, Communi D, Suarez N, et al. Les récepteurs P2Y des nucléotides extracellulaires: du clonage à la physiologie. Med Sci (Paris) 2002; 18: 965-973.
Collet JP, Choussat R, Montalescot G. L'agrégation plaquettaire et ses inhibiteurs dans les syndromes coronariens aigus. Med Sci (Paris) 2004; 20: 291-297.
Verbeuren TJ. Terutroban et récepteurs TP endothéliaux dans l'athérogenèse. Med Sci (Paris) 2006; 22: 437-443.